Clinical trials: Tumor or Lymphoma
Carcinoma, Non-Small-Cell Lung
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after…
- Trial name
- NCT00932893
- Testing
- PF-02341066, Pemetrexed, Docetaxel
- Where
- 264 sites in United States, Australia and 20 more
- Volunteers
- 347 people
- Sponsor
- Pfizer
Anemia, Leukemia
Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
RATIONALE: Darbepoetin alfa may cause the body to make more red blood cells. Red blood cells contain iron that is needed to carry oxygen to the tissues.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00661999
- Testing
- darbepoetin alfa, ferrous sulfate, sodium ferric gluconate complex in sucrose
- Where
- 2 sites in United States
- Volunteers
- 502 people
- Sponsor
- Mayo Clinic
Lymphoma, T-Cell, Peripheral
ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma
To ascertain the safety and efficacy of Istodax® in actual clinical settings in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who receive Istodax. 1. Planned registration period 4 years 2.
- Trial name
- NCT03742921
- Testing
- Istodax
- Where
- Japan
- Volunteers
- 150 people
- Sponsor
- Celgene
Leukemia
Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia
RATIONALE: Radiolabeled monoclonal antibodies can find cancer cells and carry cancer-killing substances to them without harming normal cells. This may be effective treatment for leukemia.
- Trial name
- NCT00643240
- Testing
- yttrium Y 90 anti-CD19 monoclonal antibody BU12, 111In-BU-12
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hematologic Neoplasms
Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer
Umbilical cord blood is an important source of stem cells and can be used to treat blood and immune system disorders and certain types of cancer.
- Trial name
- NCT00312429
- Testing
- Stem Cell Transplantation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Duke University
Advanced Solid Tumors, Lymphomas
Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma
This is a phase I and pharmacology study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients with Solid Tumors or Lymphoma. OBJECTIVES Primary: 1.
- Trial name
- NCT00947739
- Testing
- Camptothecin-20-O-Propionate Hydrate (CZ48)
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- New Mexico Cancer Research Alliance
Hodgkin's Lymphoma
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present.
- Trial name
- NCT00359892
- Testing
- Obatoclax mesylate (GX15-070MS)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Gemin X
Symptomatic Peripheral Artery Disease With Femoropopliteal Lesions, Moderate or Severe Claudication (Rutherford Category 2 or 3)
Korean Multicenter Registry of ELUVIA Stent for Femoropopliteal Artery Disease (K-ELUVIA Registry)
Prospective, multi-center single-arm observational study A total of 100 subjects with femoropopliteal artery disease who meet all inclusion and exclusion criteria will be included.
- Conditions
- Symptomatic Peripheral Artery Disease With Femoropopliteal Lesions, Moderate or Severe Claudication (Rutherford Category 2 or 3), Critical Limb Ischemia (Rutherford Category 4 or 5)
- Trial name
- NCT03505931
- Testing
- Implantation of Eluvia stent
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Yonsei University
Breast Cancer (Locally Advanced or Metastatic), Lymphoma
Remote Monitoring and Symptom Management Digital Application
The goal of this clinical trial is to learn if an artificial intelligence phone application called ASSIST can help patients receiving cancer treatment.
- Conditions
- Breast Cancer (Locally Advanced or Metastatic), Lymphoma, Colorectal Cancer
- Trial name
- ASSIST (NCT07553572)
- Testing
- ASSIST phone application
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Patrick C. Johnson, MD
Lymphoma, Neuroblastoma
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
This research study is evaluating a novel drug called CUDC-907 as a possible treatment for resistant (refractory) pediatric solid tumors (including neuroblastoma), lymphoma, or brain tumors.
- Conditions
- Lymphoma, Neuroblastoma, Brain Tumor, Solid Tumor
- Trial name
- NCT02909777
- Testing
- CUDC-907
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Dana-Farber Cancer Institute
Grade I or II Essential Hypertension
Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.
The objective of this study is to compare the efficacy and safety of combined administration of TAK-536CCB (Fix-dose combination of Azilsartan and Amlodipine) and Hydrochlorothiazide (HCTZ) with those of TAK-536CCB in patients…
- Trial name
- NCT02072330
- Testing
- TAK-536CCB, TAK-536CCB + Hydrochlorothiazide, Hydrochlorothiazide
- Where
- 13 sites in Japan
- Volunteers
- 353 people
- Sponsor
- Takeda
Lymphoma
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00014664
- Testing
- apolizumab
- Where
- United States
- Sponsor
- PDL BioPharma, Inc.
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
This phase I trial tests the side effects and best dose of total marrow lymphoid irradiation along with chemotherapy, with fludarabine and melphalan, with or without thiotepa, in combination with Orca-T cells for patients with…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT06195891
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin
Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)
This research is being done to develop new treatment for non-hodgkin's lymphoma in subjects whose cancer has returned or resisted treatment with chemotherapy. The investigational drug clofarabine is being used in this study.
- Trial name
- NCT00156013
- Testing
- CLOFARABINE
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Oncology Specialists, S.C.
Acute Lymphocytic Leukaemia
SAR3419 in Acute Lymphoblastic Leukemia
Primary Objective: Participants achieving an Objective Response Rate Secondary Objectives: Response duration Progression Free Survival Minimal residual disease Safety Pharmacokinetics
- Trial name
- MYRALL (NCT01440179)
- Testing
- SAR3419
- Where
- 11 sites in United States, France
- Volunteers
- 100 people
- Sponsor
- Sanofi
T-ALL
Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
The planned trial offers treatment cohorts for patients with full cytologic relapse (R/R ALL - Cohort 1), as well as for patients with molecular failure/relapse (MRD+ ALL - Cohort 2).
- Trial name
- NCT06648889
- Testing
- Isatuximab
- Where
- 15 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Goethe University
Diffuse Large B Cell Lymphoma，DLBCL
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant
Purinostat mesylate for injection (PM) was the novel and highly potent Class I a and IIb HDAC-selective inhibitors. The results of regular blood sampling analysis of the mouse B-cell lymphoma model induced by ighmyc transgenic…
- Trial name
- NCT05526313
- Testing
- Purinostat Mesylate 1.2mg/m^2, Purinostat Mesylate 2.4mg/m^2, Purinostat Mesylate 4.0mg/m^2
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL
The purposee of this study is to determine the safety and dosing of Fenretinide when given continuously for 5 days, every 3 weeks, in pediatric patients with recurrent and/or resistant acute lymphoblastic leukemia (ALL), acute…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
- Trial name
- NCT01187810
- Testing
- Fenretinide, Cytarabine, Methotrexate
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- South Plains Oncology Consortium
B-Cell Non-Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia
Study of GI001 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
This is an open-label, multi-cohort, investigator-initiated clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of GI001 in adult patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma…
- Trial name
- GI001-01 (NCT07862010)
- Testing
- GI001
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hematology department of the 920th hospital
Lymphoma, Non-Hodgkin
A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas
The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory…
- Trial name
- TRANSFORM (NCT03575351)
- Testing
- Standard of Care, JCAR017
- Where
- 54 sites in United States, Belgium and 10 more
- Volunteers
- 184 people
- Sponsor
- Celgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.